- Oops!Something went wrong.Please try again later.
FCX earnings call for the period ending September 30, 2021.
Shares of the COVID-19 vaccine makers Pfizer (NYSE: PFE), Ocugen (NASDAQ: OCGN), and Vaxart (NASDAQ: VXRT) are all moving in the wrong direction today. Specifically, Pfizer's stock is down by approximately 4%, Ocugen's equity is in the red by 5.64%, and Vaxart's shares are underwater by a hefty 8.7%, as of 12:23 p.m. ET Monday afternoon. On Sunday, the White House's chief medical advisor, Dr. Anthony Fauci, said that the preliminary data regarding the severity of the omicron variant was "encouraging."
High-growth but richly valued tech stocks have been getting hammered by the market as of late, and software cybersecurity disruptor Zscaler (NASDAQ: ZS) hasn't been exempt. As for the specific plunge today (Zscaler is up 36% in 2021 with just weeks to go until the new year), analyst Stephen Bersey at Daiwa Capital downgraded Zscaler to underperform and stuck a $286 price target on the stock. A slew of other Wall Street prognosticators waxed optimistic on Zscaler last week after the company said revenue grew 62% year over year in the last quarter, and deferred revenue (sales collected from customers, but for which service has not yet been provided) boomed 74% higher.
Investing in the metaverse will be a key theme over the next decade, one analyst says. Here are seven companies that stand to cash in.
The global war against COVID-19 has changed over the course of the past week -- and changed dramatically just this past weekend.
(Bloomberg) -- The Biden administration’s No. 2 energy official was heckled at an international oil conference after admonishing U.S. drillers to step up production in the industry’s de facto hometown.Most Read from BloombergEven in the Metaverse, Not All Identities Are Created EqualThe Hot New Trend For Hedge Funds Is—Finally—Female FoundersMeet the New Climate Refugee in Town: CoyotesAutomating the War on Noise Pollution‘Ghost Signs’ Haunt London’s Reviving NeighborhoodsDeputy Energy Secretary
The tech sell-off continued in early trading today, and alternative energy stocks were no exception. Hydrogen fuel technology company Plug Power (NASDAQ: PLUG) initially dropped more than the overall Nasdaq Composite Index, losing more than 6%. It highlighted Elon Musk's view that hydrogen fuel cells aren't the right path for electric vehicle development.
For the past 12 years, investing in growth stocks has been a moneymaking strategy. Historically low lending rates and an accommodative Federal Reserve have allowed fast-paced companies to thrive. Back in 2013, J.P. Morgan Asset Management, a division of JPMorgan Chase, released a report that compared to performance of publicly traded companies that initiated and paid a dividend between 1972 and 2012 to stocks that didn't pay a dividend over the same period.
In a matter of weeks, many growth stocks have gone from hot to cold over fears of an economic slowdown, the omicron COVID-19 variant, and valuation concerns. Lucid Group (NASDAQ: LCID) and Nio (NYSE: NIO) are two very different electric vehicle (EV) companies that are looking to make names for themselves on the global stage. Let's determine if now is the right time to buy Lucid and Nio, or if investors should run for the exits.
Dr. Stephen Hoge, president of Moderna, said Sunday that there's a risk its vaccine would decrease in effectiveness due to Omicron.
These two under-the-radar metaverse stocks can give attractive returns to retail investors in the long run.
What happened Shares of DocuSign (NASDAQ: DOCU) got shredded on Friday, but got taped back together on Monday -- to an extent. As of 11:35 a.m. ET, shares of the e-signature service are up 7% from Friday's close.
Yahoo Finance Live co-hosts Julie Hyman, Brian Cheung, and Brian Sozzi look at Nvidia's shares dipping as EU antitrust regulators pause their investigatory probe into Nvidia's acquisition of chipmaker ARM.
Across America and around the world, the omicron coronavirus variant is in full swing, and we're not even done with the delta variant yet! Despite these continuing COVID-19 fears, though, investors seem no longer so panicked about the pandemic. As of 12:45 p.m. ET Monday, shares of stocks that depend on a business model of gathering large groups of vacationers together in confined places are doing quite well, with hoteliers Las Vegas Sands (NYSE: LVS) and Park Hotels & Resorts (NYSE: PK) up 10% and 10.1%, respectively, and Norwegian Cruise Line Holdings (NYSE: NCLH) stock up 12.1%.
Many prominent investors, including Warren Buffett, David Tepper and Stan Druckenmiller, have been cautious regarding the current bull market and missed out as the stock market reached another high in recent weeks. On the other hand, technology hedge funds weren’t timid and registered double digit market beating gains. Financials, energy and industrial stocks initially suffered […]
Rising inflation is wreaking havoc on many high-growth stocks as investors fret over higher costs and reduced future valuations. Higher interest rates, which counter inflation, are also sparking fears of an economic slowdown and causing investors to rotate from dividend stocks toward lower-risk bonds. Apple (NASDAQ: AAPL) only pays a forward dividend yield of 0.5%, but its low payout ratio of 15% indicates there's still plenty of room for much higher payments.
Many growth stocks took a hit in the recent weeks, and SoFi Technologies, Inc. (NASDAQ: SOFI) has not been spared, as it dipped over 35%. As the stock reaches toward the yearly lows, we'll look into the current state of the ownership and reflect on the recent moves made by the insiders and institutions.
Lucid (LCID) shares opened 12% lower on Monday after the high-end electric vehicle startup revealed it received a subpoena from the Securities and Exchange Commission (SEC) over its recent tie-up with a special purpose acquisition company.
After a huge sell-off last month, some fears around Alibaba were allayed on Monday, and a management change was further welcomed by shareholders.
Davis Funds, an investment management firm, published its “Davis Opportunity Fund” third quarter 2021 investor letter – a copy of which can be downloaded here. In the year-to-date period through July 31, Davis Opportunity Fund returned 23.32%, outperforming the S&P 1500 Index’s 18.07% return. You can take a look at the fund’s top 5 holdings […]
Shares of CRISPR Therapeutics (NASDAQ: CRSP) sank 12.5% in November, according to data from S&P Global Market Intelligence. The biotech company published better-than-expected third-quarter earnings in the month and provided an update on its product pipeline, but its stock sold off amid bearish momentum for the broader market. Catalysts weighing on the stock market last month included rising Treasury bond yields, ongoing supply-chain issues, and the threat that the emergence of the omicron coronavirus variant would create additional economic disruptions.